Equities research analysts predict that SomaLogic, Inc. (NASDAQ:SLGC – Get Rating) will announce ($0.15) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for SomaLogic’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.13). The company is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.
On average, analysts expect that SomaLogic will report full year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.51). For the next financial year, analysts forecast that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.80) to ($0.44). Zacks’ EPS averages are a mean average based on a survey of research firms that follow SomaLogic.
SomaLogic (NASDAQ:SLGC – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01).
Shares of NASDAQ:SLGC traded up $0.23 on Monday, reaching $6.93. 784,932 shares of the company were exchanged, compared to its average volume of 1,076,658. SomaLogic has a 1-year low of $6.46 and a 1-year high of $14.72. The company has a 50-day moving average of $7.92 and a 200-day moving average of $9.96.
Several institutional investors have recently added to or reduced their stakes in SLGC. Wolverine Asset Management LLC acquired a new stake in shares of SomaLogic during the 4th quarter worth about $36,000. PNC Financial Services Group Inc. purchased a new position in shares of SomaLogic during the 3rd quarter worth about $37,000. UBS Group AG purchased a new position in shares of SomaLogic during the 3rd quarter worth about $58,000. Penserra Capital Management LLC purchased a new position in shares of SomaLogic during the 4th quarter worth about $98,000. Finally, Citadel Advisors LLC purchased a new position in shares of SomaLogic during the 3rd quarter worth about $129,000. 44.55% of the stock is currently owned by institutional investors.
About SomaLogic (Get Rating)
SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
- Get a free copy of the StockNews.com research report on SomaLogic (SLGC)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.